

Supplemental table 1 Characteristics of transfemoral transcatheter aortic valve replacement (TF-TAVR) studies

Study (year)	Device	Stroke	CAD	PVD	Af/AF	HF	T2DM,	HTN	MI	PCI	CABG	COPD
Quick, et al. (2013)	CoreValve	NR	NR	NR	NR	NR	13	NR	NR	20		16
Ayhan, et al. (2014)	SAPIEN XT	NR	38	11	15	NR	14	42	NR	NR	NR	28
Okada, et al. (2014)	SAPIEN	NR	9	NR	NR	13	5	9	2	3	5	NR
Crouch, et al. (2015)	SAPIEN XT	NR	8	NR	6	NR	10	24	6	8	NR	11
Gronlykke, et al. (2017)	CoreValve	NR	NR	6	34	NR	19	83	5	10	NR	NR
Keyl, et al. (2016)	SAPIEN XT	2	14	5	NR	NR	6	18	NR	NR	NR	5
Musa,, et al. (2016)	CoreValve (N=46)	10	NR	13	14	NR	11	NR	11	14	16	13
	Lotus valve (N=10)											

Abbreviations: Data presented as mean \pm standard deviation (SD) or number; pre-AVA, pre-operation aortic valve area; STS, Society of Thoracic Surgery; NYHA, New York Heart Association; CAD, coronary artery disease; PVD, Peripheral vascular disease; Af, atrial fibrillation; AF, atrial flutter; HF, heart failure; T2DM, Type 2 Diabetes Mellitus; HTN, hypertension; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; AS, aortic stenosis; NR, not reported; a included 2 patients who underwent trans-subclavian artery TAVR; b included 4 patients who underwent trans-subclavian artery TAVR; c included 3 patients who underwent trans-subclavian artery TAVR, 1 patient who underwent trans-carotid artery TAVR and 1 patient who underwent direct trans-aortic TAVR.